Related Experiment Video
Updated: Jun 26, 2026

Preparation of Primary Myogenic Precursor Cell/Myoblast Cultures from Basal Vertebrate Lineages
Published on: April 30, 2014
Caveolin-3 regulates myostatin signaling. Mini-review
1Division of Neurology, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki-City, Okayama 701-0192, Japan.
Abstract:
Caveolins, components of the uncoated invaginations of plasma membrane, regulate signal transduction and vesicular trafflicking. Loss of caveolin-3, resulting from dominant negative mutations of caveolin-3 causes autosomal dominant limb-girdle muscular dystrophy (LGMD) 1C and autosomal dominant rippling muscle disease (AD-RMD). Myostatin, a member of the muscle-specific transforming growth factor (TGF)-beta superfamily, negatively regulates skeletal muscle volume. Herein we review caveolin-3 suppressing of activation of type I myostatin receptor, thereby inhibiting subsequent intracellular signaling. In addition, a mouse model of LGMD1C has shown atrophic myopathy with enhanced myostatin signaling. Myostatin inhibition ameliorates muscular phenotype in the model mouse, accompanied by normalized myostatin signaling. Enhanced myostatin signaling by caveolin-3 mutation in human may contribute to the pathogenesis of LGMD1C. Therefore, myostatin inhibition therapy may be a promising treatment for patients with LGMD1C. More recent studies concerning regulation of TGF-beta superfamily signaling by caveolins have provided new insights into the pathogenesis of several human diseases.
Insights
Caveolin-3 loss causes muscular dystrophy by enhancing myostatin signaling. Inhibiting myostatin shows promise for treating limb-girdle muscular dystrophy (LGMD) 1C by normalizing this signaling pathway.
Area of Science:
- Cell biology
- Molecular biology
- Genetics
Background:
- Caveolins are integral membrane proteins regulating cellular processes.
- Mutations in caveolin-3 cause muscular dystrophies like LGMD1C.
- Myostatin is a key negative regulator of skeletal muscle mass.
Purpose of the Study:
- To review the role of caveolin-3 in myostatin signaling.
- To explore the therapeutic potential of myostatin inhibition in LGMD1C.
Main Methods:
- Review of existing literature on caveolin-3 and myostatin.
- Analysis of a mouse model for LGMD1C.
- Examination of myostatin signaling pathways.
Main Results:
- Caveolin-3 normally suppresses myostatin receptor activation.
- LGMD1C mouse models exhibit muscle atrophy due to enhanced myostatin signaling.
- Myostatin inhibition improved muscle phenotype in the mouse model.
Conclusions:
- Caveolin-3 mutations may lead to LGMD1C pathogenesis via enhanced myostatin signaling.
- Myostatin inhibition represents a potential therapeutic strategy for LGMD1C patients.
Related Concept Videos
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
TGF - β Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
PI3K/mTOR/AKT Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...

